echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Immunology News > Nat Commun: Significant progress!

    Nat Commun: Significant progress!

    • Last Update: 2021-06-19
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    News April 23, 2021//---There is still no medicine or vaccine to cure HIV/AIDS, and 37 million people around the world are still infected with HIV


    Tissue mononuclear phagocytes (MNP) specialize in pathogen detection and antigen presentation




    All MNP subgroups express the key HIV entry receptor CD4, but cDC1 and LC express very low levels of HIV entry co-receptor CCR5, and these two MNP subgroups are also different from other MNP subgroups because they express There are far fewer lectin receptors


    DC-SIGN, which binds to HIV, was previously considered a DC marker and was found to be involved in HIV capture and transfer to T cells




    These authors further observed that all CD14-expressing cells (hereinafter referred to as CD14+ cells) subpopulations can take up HIV efficiently, but MDDC take up significantly more HIV


    These authors also found that MDDC expresses higher levels of CCR5 than other CD14+ cell populations.


    Recently, it has been found that cDC2 located under the epithelium exists in the epidermis of human anogenital skin tissues.




    In summary, these authors found that HIV can cross the epithelial surface and interact with the subepithelial MNP of anal-genital explants, and identified human anal-genital tissues and colon tissues that HIV may encounter during sexual transmission.


    Reference materials:


    References:

    Jake W.
    Rhodes et al.
    Human anogenital monocyte-derived dendritic cells and langerin+cDC2 are major HIV target cells .
    Nature Communications, 2021, doi:10.
    1038/s41467-021-22375-x.
    Human anogenital monocyte-derived dendritic cells and langerin+cDC2 are major HIV target cells
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.